黑人高风险APOL1基因型膜性肾病患者的肾脏病进展
本研究纵向随访了118例黑人膜性肾病患者(16例高风险APOL1基因型,102例低风险)及572例非黑人膜性肾病患者。高风险APOL1基因型患者eGFR下降斜率更陡(-16±2 vs 低风险-4±0.8 vs 非黑人-2.0±0.4 ml/min per 1.73 m² per year,P<0.0001),进展至肾衰竭更快。
要点
- 黑人膜性肾病患者中高风险APOL1基因型占14%(16/118)。
- 高风险APOL1基因型患者eGFR下降斜率-16±2 ml/min per 1.73 m² per year,较低风险组和非黑人组更陡。
- 高风险APOL1基因型患者进展至肾衰竭的时间更快。
核心结论
- 黑人膜性肾病患者中高风险APOL1变异患病率与普通黑人群体(10%-15%)相当,但高风险基因型与更差的eGFR下降和更快的肾衰竭进展相关。
研究设计与样本
- 纵向随访研究,纳入肾小球疾病协作网络或Cure Glomerulonephropathy网络中具有DNA或基因分型数据的黑人膜性肾病患者(n=118)及非黑人膜性肾病患者(n=572)。
主要发现
- 118例黑人膜性肾病患者中,16例(14%)为高风险APOL1基因型(两个风险等位基因),102例(86%)为低风险基因型(零或一个风险等位基因,分别为n=53和n=49)。
- 高风险APOL1基因型患者发病年龄显著低于低风险APOL1基因型患者和非黑人膜性肾病患者(n=572)。
- 各组发病时eGFR无差异,但eGFR下降斜率在高风险APOL1基因型患者为-16±2 ml/min per 1.73 m² per year,低风险APOL1基因型患者为-4±0.8 ml/min per 1.73 m² per year,非黑人膜性肾病患者为-2.0±0.4 ml/min per 1.73 m² per year(P<0.0001)。
- 高风险APOL1基因型患者进展至肾衰竭的时间较低风险APOL1基因型患者和非黑人膜性肾病患者更快。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disparity in CKD progression among Black individuals persists in glomerular diseases. Genetic variants in the apolipoprotein L1 ( APOL1 ) gene in the Black population contribute to kidney disease, but the influence in membranous nephropathy remains unknown. METHODS: Longitudinally followed participants enrolled in the Glomerular Disease Collaborative Network or Cure Glomerulonephropathy Network were included if they had DNA or genotyping available for APOL1 (Black participants with membranous nephropathy) or had membranous nephropathy but were not Black. eGFR slopes were estimated using linear mixed-effects models with random effects and adjusting for covariates and interaction terms of covariates. Fisher exact test, Kruskal-Wallis test, and Kaplan-Meier curves with log-rank tests were used to compare groups. RESULTS: Among 118 Black membranous nephropathy participants, 16 (14%) had high-risk APOL1 genotype (two risk alleles) and 102 (86%) had low-risk APOL1 genotype (zero or one risk alleles, n =53 and n =49, respectively). High-risk APOL1 membranous nephropathy participants were notably younger at disease onset than low-risk APOL1 and membranous nephropathy participants that were not Black ( n =572). eGFR at disease onset was not different between groups, although eGFR decline (slope) was steeper in participants with high-risk APOL1 genotype (-16±2 [±SE] ml/min per 1.73 m 2 per year) compared with low-risk APOL1 genotype (-4±0.8 ml/min per 1.73 m 2 per year) or membranous nephropathy participants that did not identify themselves as Black (-2.0±0.4 ml/min per 1.73 m 2 per year) ( P <0.0001). Time to kidney failure was faster in the high-risk APOL1 genotype than low-risk APOL1 genotype or membranous nephropathy participants that were not Black. CONCLUSIONS: The prevalence of high-risk APOL1 variant among Black membranous nephropathy participants is comparable with the general Black population (10%-15%), yet the high-risk genotype was associated with worse eGFR decline and faster time to kidney failure compared with low-risk genotype and participants that were not Black.
引用
- Chen DP, Henderson CD, Anguiano J, et al. Kidney Disease Progression in Membranous Nephropathy among Black Participants with High-Risk APOL1 Genotype. Clin J Am Soc Nephrol. 2023. PMID: 36763808. doi:10.2215/CJN.0000000000000070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。